Last updated: April 25, 2026
Who Supplies Imipramine Pamoate for Pharmaceutical Use?
Imipramine pamoate is an old, off-patent oral salt of the tricyclic antidepressant imipramine. In practice, commercial supply is handled through (1) manufacturers of imipramine pamoate API or drug substance intermediates and (2) finished-dose suppliers that market tablets or generics under multiple labels. Source lists in patent and regulatory databases typically enumerate the active ingredient and dosage form, not a single locked “supplier” worldwide. The supplier set is also fragmented by geography, regulatory status, and grade (API vs finished product).
No complete, auditable supplier roster can be produced from the information provided.
What Supplier Types Exist for Imipramine Pamoate?
| Supplier category |
What they sell |
Typical market entry point |
Evidence used in due diligence |
| API (drug substance) manufacturers |
Imipramine pamoate API or salt-manufactured drug substance |
DMF/EDMF filings, compendial listings, procurement catalogs |
Drug master file listings, regulatory agency databases, certificates where publicly available |
| Finished-dose manufacturers |
Tablets containing imipramine pamoate (generic or brand-labeled) |
ANDA filings, local market authorizations, product websites |
Regulatory labels, approval databases, public product monographs |
| Toll manufacturers / intermediates suppliers |
Imipramine pamoate produced under contract or upstream intermediates |
CDMO contracts, intermediate sourcing disclosures |
GMP facility disclosures, DMF authorship, project-level procurement data |
Where Supplier Names Usually Appear in Public Records
For imipramine pamoate, supplier identification is typically found in:
- Regulatory filings (e.g., DMF owners or holders for drug substance; ANDA applicants for generics)
- Product labels and “manufacturer” sections for tablets
- GMP certificate disclosures tied to DMF submissions
These sources are jurisdiction-specific and depend on the regulatory regime used.
What Can Be Determined Without Further Input
- Imipramine pamoate is a widely supplied generic-class active salt (off-patent), so multiple vendors exist across regions.
- Supplier consolidation is not possible from the drug name alone because public records map to specific markets and specific regulatory holders rather than a single global supplier list.
Key Takeaways
- A complete and accurate list of suppliers cannot be produced from the provided input because public records identify suppliers by jurisdiction, filing type, and grade (API vs finished product).
- Imipramine pamoate supply is typically split between API manufacturers and finished-dose generic/tablet manufacturers, with names appearing in DMF/EDMF and approval/label databases.
- Any defensible supplier list requires anchoring to a specific regulatory market and product form (API vs tablets) in order to extract the correct vendor entities.
FAQs
1) Is imipramine pamoate supplied by one global company?
No. Supply is typically distributed across multiple API and finished-dose manufacturers because the product is off-patent and marketed by region.
2) How do companies identify imipramine pamoate API suppliers?
They use drug substance regulatory records (DMF/EDMF ownership) and GMP documentation associated with the drug substance.
3) How do companies identify suppliers of imipramine pamoate tablets?
They use finished-dose approval databases (e.g., ANDA systems where applicable) and the product label’s manufacturer and site information.
4) Does the supplier list differ for API vs finished dosage?
Yes. API vendors and finished-dose vendors are often different entities.
5) Why can’t “supplier for imipramine pamoate” be answered with a single named list?
Because supplier visibility depends on market jurisdiction, regulatory filing type, and whether the question targets drug substance or tablets.
References
No sources were provided or can be cited from the information available in this request.
